

# Karl Josef Langen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7708421/publications.pdf>

Version: 2024-02-01

302  
papers

11,992  
citations

20817

60  
h-index

37204

96  
g-index

320  
all docs

320  
docs citations

320  
times ranked

8208  
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-stroke treatment with argon preserved neurons and attenuated microglia/macrophage activation long-termly in a rat model of transient middle cerebral artery occlusion (tMCAO). <i>Scientific Reports</i> , 2022, 12, 691.	3.3	2
2	mGluR5 binding changes during a mismatch negativity task in a multimodal protocol with [11C]ABP688 PET/MR-EEG. <i>Translational Psychiatry</i> , 2022, 12, 6.	4.8	7
3	Letter to the Editor: <sup>18</sup> F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study. <i>J Nucl Med</i> 2022; 63:147-157. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.122.263837.	5.0	0
4	Use of advanced neuroimaging and artificial intelligence in meningiomas. <i>Brain Pathology</i> , 2022, 32, e13015.	4.1	11
5	The role of 11C-methionine PET in patients with newly diagnosed WHO grade 2 or 3 gliomas. <i>Neuro-Oncology</i> , 2022, , .	1.2	1
6	Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group. <i>Neuro-Oncology</i> , 2022, 24, 1815-1826.	1.2	14
7	Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression. <i>Journal of Neuro-Oncology</i> , 2022, 159, 519-529.	2.9	11
8	Two Decades of Brain Tumour Imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Jülich Experience. <i>Cancers</i> , 2022, 14, 3336.	3.7	8
9	Comparison of EEG microstates with resting state fMRI and FDG-PET measures in the default mode network via simultaneously recorded trimodal (PET/MR/EEG) data. <i>Human Brain Mapping</i> , 2021, 42, 4122-4133.	3.6	32
10	Early treatment response assessment using <sup>18</sup> F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254243.	5.0	25
11	Radiomics in neuro-oncology: Basics, workflow, and applications. <i>Methods</i> , 2021, 188, 112-121.	3.8	85
12	Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology. <i>Nuclear Medicine and Biology</i> , 2021, 92, 78-84.	0.6	30
13	Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1956-1965.	6.4	37
14	Treatment Monitoring of Immunotherapy and Targeted Therapy Using <sup>18</sup> F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences. <i>Journal of Nuclear Medicine</i> , 2021, 62, 464-470.	5.0	25
15	Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	1.8	0
16	Combined 18F-FET PET and diffusion kurtosis MRI in posttreatment glioblastoma: differentiation of true progression from treatment-related changes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab044.	0.7	4
17	A Linearized Fit Model for Robust Shape Parameterization of FET-PET TACs. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 1-1.	8.9	2
18	Evaluation of FET PET Radiomics Feature Repeatability in Glioma Patients. <i>Cancers</i> , 2021, 13, 647.	3.7	17

#	ARTICLE	IF	CITATIONS
19	Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. <i>Neuro-Oncology</i> , 2021, 23, 881-893.	1.2	75
20	A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. <i>Molecules</i> , 2021, 26, 1590.	3.8	6
21	Finding New Communities: A Principle of Neuronal Network Reorganization in Alzheimer's Disease. <i>Brain Connectivity</i> , 2021, 11, 225-238.	1.7	6
22	Diagnosis of Pseudoprogression Following Lomustineâ€“Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. <i>Clinical Cancer Research</i> , 2021, 27, 3704-3713.	7.0	19
23	Lesion-Function Analysis from Multimodal Imaging and Normative Brain Atlases for Prediction of Cognitive Deficits in Glioma Patients. <i>Cancers</i> , 2021, 13, 2373.	3.7	8
24	Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1G93A Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7066.	4.1	3
25	In Reply to the Letter to the Editor Regarding â€œ18F-DOPA PET in Medulloblastoma: Two Case Reportsâ€. <i>World Neurosurgery</i> , 2021, 150, 255.	1.3	0
26	PEAÎ² Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimerâ€™s Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7062.	4.1	4
27	Differential neural structures, intrinsic functional connectivity, and episodic memory in subjective cognitive decline and healthy controls. <i>Neurobiology of Aging</i> , 2021, 105, 159-173.	3.1	2
28	A Fast Protocol for Multiparametric Characterisation of Diffusion in the Brain and Brain Tumours. <i>Frontiers in Oncology</i> , 2021, 11, 554205.	2.8	1
29	Protease Responsive Nanogels for Transcytosis across the Bloodâˆ“Brain Barrier and Intracellular Delivery of Radiopharmaceuticals to Brain Tumor Cells. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100812.	7.6	18
30	Sex-Related Motor Deficits in the Tau-P301L Mouse Model. <i>Biomedicines</i> , 2021, 9, 1160.	3.2	4
31	18F-FET-PET-guided gross total resection improves overall survival in patients with WHO grade III/IV glioma: moving towards a multimodal imaging-guided resection. <i>Journal of Neuro-Oncology</i> , 2021, 155, 71-80.	2.9	9
32	Excitatoryâ€“inhibitory balance within EEG microstates and resting-state fMRI networks: assessed via simultaneous trimodal PETâ€“MRâ€“EEG imaging. <i>Translational Psychiatry</i> , 2021, 11, 60.	4.8	21
33	Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement. <i>Scientific Reports</i> , 2021, 11, 20828.	3.3	9
34	Case Report: Disruption of Resting-State Networks and Cognitive Deficits After Whole Brain Irradiation for Singular Brain Metastasis. <i>Frontiers in Neuroscience</i> , 2021, 15, 738708.	2.8	3
35	Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimerâ€™s Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography. <i>Frontiers in Neuroscience</i> , 2021, 15, 699926.	2.8	5
36	NIMG-27. REGORAFENIB RESPONSE ASSESSMENT USING FET PET IN PATIENTS WITH PROGRESSIVE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi134-vi134.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Case Report: Detection of Symptomatic Treatment-Related Changes in a Patient With Anaplastic Oligodendroglioma Using FET PET. <i>Frontiers in Oncology</i> , 2021, 11, 735388.	2.8	0
38	Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 198-207.	2.6	16
39	<sup>18</sup> F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience. <i>Journal of Nuclear Medicine</i> , 2020, 61, 505-511.	5.0	47
40	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	1.2	94
41	Combined FET PET/ADC mapping: improved imaging of glioma infiltration?. <i>Neuro-Oncology</i> , 2020, 22, 313-314.	1.2	0
42	Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 137-146.	2.8	8
43	Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 9-15.	2.4	10
44	Bolus infusion scheme for the adjustment of steady state [11C]Flumazenil levels in the grey matter and in the blood plasma for neuroreceptor imaging. <i>NeuroImage</i> , 2020, 221, 117160.	4.2	2
45	Relaxometry and quantification in sodium MRI of cerebral gliomas: A FET-PET and MRI small-scale study. <i>NMR in Biomedicine</i> , 2020, 33, e4361.	2.8	7
46	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. <i>Cancers</i> , 2020, 12, 3080.	3.7	25
47	Reply: Flare Phenomenon in <i>O</i> -(2-[ <sup>18</sup> F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1852-1852.	5.0	1
48	FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation. <i>Cancers</i> , 2020, 12, 3835.	3.7	55
49	Predicting experimental success: A retrospective case-control study using the rat intraluminal thread model of stroke. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	2
50	Investigation of Cerebral O-(2-[18F]Fluoroethyl)-L-Tyrosine Uptake in Rat Epilepsy Models. <i>Molecular Imaging and Biology</i> , 2020, 22, 1255-1265.	2.6	3
51	Imaging challenges following newer treatment options: are companion diagnostics required in neurooncology?. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 651-652.	3.1	0
52	Role of the default mode resting-state network for cognitive functioning in malignant glioma patients following multimodal treatment. <i>NeuroImage: Clinical</i> , 2020, 27, 102287.	2.7	18
53	mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia. <i>Human Brain Mapping</i> , 2020, 41, 2762-2781.	3.6	20
54	Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. <i>Molecules</i> , 2020, 25, 1471.	3.8	33

#	ARTICLE	IF	CITATIONS
55	PET/MRI Radiomics in Patients With Brain Metastases. <i>Frontiers in Neurology</i> , 2020, 11, 1.	2.4	210
56	Invasive versus noninvasive mapping of the motor cortex. <i>Human Brain Mapping</i> , 2020, 41, 3970-3983.	3.6	14
57	Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[18F]-fluoroethyl)-l-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1486-1495.	6.4	16
58	Flare Phenomenon in O-(2-18F-Fluoroethyl)-l-Tyrosine PET After Resection of Gliomas. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1294-1299.	5.0	10
59	Effect of Zolpidem in the Aftermath of Traumatic Brain Injury: An MEG Study. <i>Case Reports in Neurological Medicine</i> , 2020, 2020, 1-8.	0.4	7
60	FET and FDOPA PET Imaging in Glioma. , 2020, , 211-221.		2
61	Feature-based PET/MRI radiomics in patients with brain tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, iv15-iv21.	0.7	13
62	High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes. <i>EJNMMI Research</i> , 2020, 10, 55.	2.5	13
63	An in vivo multimodal feasibility study in a rat brain tumour model using flexible multinuclear MR and PET systems. <i>EJNMMI Physics</i> , 2020, 7, 50.	2.7	3
64	The Role of Radionuclide Diagnostic Methods in Neuro-Oncology. <i>Vestnik Rentgenologii I Radiologii</i> , 2020, 101, 221-234.	0.2	0
65	Influence of Dexamethasone on O-(2-[18F]-Fluoroethyl)-l-Tyrosine Uptake in the Human Brain and Quantification of Tumor Uptake. <i>Molecular Imaging and Biology</i> , 2019, 21, 168-174.	2.6	11
66	The Jülich Experience With Simultaneous 3T MR-BrainPET: Methods and Technology. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 352-362.	3.7	14
67	A $\beta$ 2 Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. <i>Molecular Neurobiology</i> , 2019, 56, 2211-2223.	4.0	29
68	Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD. <i>NeuroImage: Clinical</i> , 2019, 24, 101978.	2.7	11
69	Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. <i>British Journal of Neurosurgery</i> , 2019, , 1-7.	0.8	11
70	Current status of PET imaging in neuro-oncology. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz010.	0.7	78
71	Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz038.	0.7	10
72	Comment on "Hypometabolic gliomas on FET-PET" is there an inverted U-curve for survival? <i>Neuro-Oncology</i> , 2019, 21, 1612-1613.	1.2	9

#	ARTICLE	IF	CITATIONS
73	An MR technique for simultaneous quantitative imaging of water content, conductivity and susceptibility, with application to brain tumours using a 3T hybrid MR-PET scanner. <i>Scientific Reports</i> , 2019, 9, 88.	3.3	13
74	Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients. <i>Cancers</i> , 2019, 11, 153.	3.7	51
75	Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1889-1901.	6.4	47
76	Post-stroke treatment with argon attenuated brain injury, reduced brain inflammation and enhanced M2 microglia/macrophage polarization: a randomized controlled animal study. <i>Critical Care</i> , 2019, 23, 198.	5.8	36
77	Photopenic defects on O-(2-[ <sup>18</sup> F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. <i>Neuro-Oncology</i> , 2019, 21, 1331-1338.	1.2	31
78	Treatment-Related Uptake of <sup>18</sup> F-Fluoroethyl)-l-Tyrosine and l-[Methyl- <sup>3</sup> H]-Methionine After Tumor Resection in Rat Glioma Models. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1373-1379.	5.0	7
79	Dynamic FET PET Imaging of a "Butterfly" IDH-Wildtype Anaplastic Astrocytoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, e581-e582.	1.3	3
80	Cis-4-[ <sup>18</sup> F]fluoro-D-proline detects neurodegeneration in patients with akinetic-rigid parkinsonism. <i>Nuclear Medicine Communications</i> , 2019, 40, 383-387.	1.1	4
81	Deceleration of the neurodegenerative phenotype in pyroglutamate- $\text{A}\beta^2$ accumulating transgenic mice by oral treatment with the $\text{A}\beta^2$ oligomer eliminating compound RD2. <i>Neurobiology of Disease</i> , 2019, 124, 36-45.	4.4	13
82	Simultaneous PET-MR-EEG: Technology, Challenges and Application in Clinical Neuroscience. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 377-385.	3.7	9
83	PET imaging in patients with brain metastasis" report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019, 21, 585-595.	1.2	139
84	FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 591-602.	6.4	74
85	Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 295-311.	4.1	20
86	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ <sup>18</sup> F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 540-557.	6.4	348
87	No detectable effects of acute tryptophan depletion on short-term immune system cytokine levels in healthy adults. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 416-423.	2.6	5
88	Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13525-e13525.	1.6	3
89	O-(2-[ <sup>18</sup> F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results. <i>Current Radiopharmaceuticals</i> , 2019, 12, 201-210.	0.8	17
90	Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1031-1040.	6.4	17

#	ARTICLE	IF	CITATIONS
91	Investigation of cis-4-[18F]Fluoro-D-Proline Uptake in Human Brain Tumors After Multimodal Treatment. <i>Molecular Imaging and Biology</i> , 2018, 20, 1035-1043.	2.6	6
92	Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, 19-25.	0.7	30
93	Comparison of O-(2- 18 F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study. <i>World Neurosurgery</i> , 2018, 113, e727-e737.	1.3	34
94	Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1626-1635.	6.4	14
95	Spatial Relationship of Glioma Volume Derived from <sup>18</sup> F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 603-609.	5.0	27
96	Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 114, 93-102.	4.0	11
97	A $\beta$ oligomer eliminating compounds interfere successfully with pEA $\beta$ (3 $\times$ 42) induced motor neurodegenerative phenotype in transgenic mice. <i>Neuropeptides</i> , 2018, 67, 27-35.	2.2	9
98	Static and dynamic 18F $\beta$ -FET PET for the characterization of gliomas defined by IDH and 1p/19q status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 443-451.	6.4	95
99	Evaluation of factors influencing 18F-FET uptake in the brain. <i>NeuroImage: Clinical</i> , 2018, 17, 491-497.	2.7	18
100	FET PET in Primary Central Nervous System Vasculitis. <i>Clinical Nuclear Medicine</i> , 2018, 43, e322-e323.	1.3	7
101	NIMG-01. A BLINDED IMAGE EVALUATION STUDY TO DETERMINE THE DIAGNOSTIC EFFICACY OF 18F-FLUCICLOVINE PET, AS AN ADJUNCT TO MRI IMAGING, IN ADULTS WITH GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi175-vi176.	1.2	0
102	NIMG-79. EARLY TREATMENT RESPONSE ASSESSMENT USING O-(2-18F-FLUOROETHYL)-L-TYROSINE (FET) PET COMPARED TO MRI IN MALIGNANT GLIOMAS TREATED WITH ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi193-vi193.	1.2	2
103	Update on amino acid PET of brain tumours. <i>Current Opinion in Neurology</i> , 2018, 31, 354-361.	3.6	31
104	On the Extraction and Analysis of Graphs From Resting-State fMRI to Support a Correct and Robust Diagnostic Tool for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 528.	2.8	7
105	Predicting IDH genotype in gliomas using FET PET radiomics. <i>Scientific Reports</i> , 2018, 8, 13328.	3.3	90
106	Correlation of Dynamic O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography, Conventional Magnetic Resonance Imaging, and Whole-Brain Histopathology in a Pretreated Glioblastoma: A Postmortem Study. <i>World Neurosurgery</i> , 2018, 119, e653-e660.	1.3	3
107	Comprehensive Characterization of the Pyroglutamate Amyloid- $\beta$ Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 115-130.	2.6	10
108	Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2377-2386.	6.4	45

#	ARTICLE	IF	CITATIONS
109	Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas. PLoS ONE, 2018, 13, e0199379.	2.5	19
110	In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 859-873.	2.6	10
111	Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. NeuroImage: Clinical, 2018, 20, 537-542.	2.7	113
112	Investigational PET tracers for high-grade gliomas. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 281-294.	0.7	10
113	Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus <sup>18</sup> F-FDG PET/CT in differentiating brain tumor progression from radiation injury. Neuro-Oncology, 2017, 19, now283.	1.2	0
114	Dynamic <sup>18</sup> F-fluoroethyl-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro-Oncology, 2017, 19, now149.	1.2	91
115	Functional MRI vs. navigated TMS to optimize M1 seed volume delineation for DTI tractography. A prospective study in patients with brain tumours adjacent to the corticospinal tract. NeuroImage: Clinical, 2017, 13, 297-309.	2.7	44
116	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. NeuroImage: Clinical, 2017, 13, 386-394.	2.7	101
117	Influence of Bevacizumab on Blood-Brain Barrier Permeability and <sup>18</sup> F-Fluoroethyl-L-Tyrosine Uptake in Rat Gliomas. Journal of Nuclear Medicine, 2017, 58, 700-705.	5.0	27
118	Amino acid PET and MR perfusion imaging in brain tumours. Clinical and Translational Imaging, 2017, 5, 209-223.	2.1	54
119	Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[ <sup>18</sup> F]Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.8	76
120	Functional Disintegration of the Default Mode Network in Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 169-187.	2.6	81
121	PET imaging in patients with meningioma—report of the RANO/PET Group. Neuro-Oncology, 2017, 19, 1576-1587.	1.2	157
122	Advances in neuro-oncology imaging. Nature Reviews Neurology, 2017, 13, 279-289.	10.1	264
123	O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro-Oncology, 2017, 19, 1271-1278.	1.2	27
124	Amino acid PET in neuro-oncology: applications in the clinic. Expert Review of Anticancer Therapy, 2017, 17, 395-397.	2.4	21
125	AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-L-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells. Clinical Nuclear Medicine, 2017, 42, e506-e508.	1.3	10
126	TSPO PET using 18F-GE-180: a new perspective in neurooncology?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2227-2229.	6.4	5



#	ARTICLE	IF	CITATIONS
127	Comparison of 18F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2257-2265.	6.4	60
128	Pseudoprogression after glioma therapy: an update. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1109-1115.	2.8	40
129	Methods for molecular imaging of brain tumours in a hybrid MR-PET context: Water content, T2 <sup>*</sup> , diffusion indices and FET-PET. <i>Methods</i> , 2017, 130, 135-151.	3.8	13
130	Dissociated Crossed Speech Areas in a Tumour Patient. <i>Case Reports in Neurology</i> , 2017, 9, 131-136.	0.7	7
131	Bone regeneration induced by a 3D architected hydrogel in a rat critical-size calvarial defect. <i>Biomaterials</i> , 2017, 113, 158-169.	11.4	58
132	Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans. <i>European Radiology</i> , 2017, 27, 2916-2927.	4.5	81
133	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by <sup>18</sup> F-Fluoroethyl-L-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. <i>Journal of Nuclear Medicine</i> , 2017, 58, 129-137.	5.0	45
134	Influence of blood-brain barrier permeability on O-(2-18F-fluoroethyl)-L-tyrosine uptake in rat gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 408-416.	6.4	21
135	NIMG-32. DIFFERENTIATION OF PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS BASED ON FET PET RADIOMICS. <i>Neuro-Oncology</i> , 2017, 19, vi148-vi149.	1.2	3
136	Osteopontin Augments M2 Microglia Response and Separates M1- and M2-Polarized Microglial Activation in Permanent Focal Cerebral Ischemia. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	3.0	39
137	O-(2-[18F]fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres. <i>EJNMMI Research</i> , 2017, 7, 64.	2.5	14
138	Positron-Emission-Tomography in Diffuse Low-Grade Gliomas. , 2017, , 263-286.		4
139	18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 584-589.	5.0	36
140	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. <i>Oncology Reports</i> , 2017, 38, 3291-3296.	2.6	46
141	Positron emission tomography imaging in diffuse intrinsic pontine glioma. <i>Annals of Translational Medicine</i> , 2017, 5, 312-312.	1.7	1
142	Amino Acid PET – An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?. <i>Frontiers in Neurology</i> , 2016, 7, 120.	2.4	37
143	Imaging of sodium in the brain: a brief review. <i>NMR in Biomedicine</i> , 2016, 29, 162-174.	2.8	45
144	Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. <i>Radiation Oncology</i> , 2016, 11, 87.	2.7	30

#	ARTICLE	IF	CITATIONS
145	The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. <i>Neuro-Oncology</i> , 2016, 19, now243.	1.2	8
146	Letter to the Editor: “Comparing the Volume of Brain Metastases in F-18-FET-PET and MRI”. <i>World Neurosurgery</i> , 2016, 89, 722.	1.3	1
147	Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 31-38.	4.0	21
148	Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 44, 114-126.	3.1	63
149	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1462-1464.	1.2	65
150	PET imaging in glioma: is it time for mainstream practice?. <i>Neuro-Oncology</i> , 2016, 18, 1193-1194.	1.2	2
151	18F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports. <i>World Neurosurgery</i> , 2016, 93, 490.e7-490.e11.	1.3	6
152	Blood-brain barrier penetration of an A $\beta$ -targeted, arginine-rich, d-enantiomeric peptide. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 2717-2724.	2.6	21
153	Amino acid PET for brain tumours “ready for the clinic?”. <i>Nature Reviews Neurology</i> , 2016, 12, 375-376.	10.1	60
154	Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1115-1123.	6.4	15
155	Multimodal Imaging in Malignant Brain Tumors: Enhancing the Preoperative Risk Evaluation for Motor Deficits with a Combined Hybrid MRI-PET and Navigated Transcranial Magnetic Stimulation Approach. <i>American Journal of Neuroradiology</i> , 2016, 37, 266-273.	2.4	14
156	Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. <i>Clinical Cancer Research</i> , 2016, 22, 2190-2196.	7.0	106
157	Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic $\beta$ -Amyloid Oligomers. <i>Pharmaceutical Research</i> , 2016, 33, 328-336.	3.5	35
158	Dietary tryptophan depletion in humans using a simplified two amino acid formula “A pilot study. <i>Food and Nutrition Research</i> , 2016, 60, 29272.	2.6	3
159	QIAD assay for quantitating a compound’s efficacy in elimination of toxic A $\beta$ oligomers. <i>Scientific Reports</i> , 2015, 5, 13222.	3.3	39
160	Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4. <i>Stem Cell Research and Therapy</i> , 2015, 6, 99.	5.5	68
161	Characterization of [ <sup>123</sup> I]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative <i>in vitro</i> autoradiography. <i>Synapse</i> , 2015, 69, 497-504.	1.2	9
162	Loss of Autonoetic Awareness of Recent Autobiographical Episodes and Accelerated Long-Term Forgetting in a Patient with Previously Unrecognized Glutamic Acid Decarboxylase Antibody Related Limbic Encephalitis. <i>Frontiers in Neurology</i> , 2015, 6, 130.	2.4	48

#	ARTICLE	IF	CITATIONS
163	Simultaneous trimodal MR-PET-EEG imaging for the investigation of resting state networks in humans. <i>EJNMMI Physics</i> , 2015, 2, A71.	2.7	2
164	Brain connectivity study of brain tumor patients using MR-PET data: preliminary results. <i>EJNMMI Physics</i> , 2015, 2, A75.	2.7	1
165	Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0128553.	2.5	29
166	NIMG-28 TREATMENT RESPONSE EVALUATION USING FET PET COMPARED TO STANDARD MRI IN GLIOBLASTOMA PATIENTS AT FIRST RECURRENCE TREATED WITH BEVACIZUMAB PLUS LOMUSTINE. <i>Neuro-Oncology</i> , 2015, 17, v159.4-v160.	1.2	0
167	Improved nTMS- and DTI-derived CST tractography through anatomical ROI seeding on anterior pontine level compared to internal capsule. <i>NeuroImage: Clinical</i> , 2015, 7, 424-437.	2.7	65
168	Uptake and tracer kinetics of O-(2-18F-fluoroethyl)-l-tyrosine in meningiomas: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 459-467.	6.4	24
169	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-l-tyrosine PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 685-695.	6.4	216
170	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. <i>Neuro-Oncology</i> , 2015, 17, 1434-1444.	1.2	144
171	Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 905-915.	6.4	58
172	Dual-time-point O-(2-[18F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. <i>European Radiology</i> , 2015, 25, 3017-3024.	4.5	76
173	The Usefulness of Dynamic <sup>18</sup> F-Fluoroethyl)-l-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents. <i>Journal of Nuclear Medicine</i> , 2015, 56, 88-92.	5.0	64
174	The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. <i>Neuro-Oncology</i> , 2015, 17, 1293-300.	1.2	134
175	Automatic derivation of an MR-PET image-based input function for quantification of 18F-FET. <i>EJNMMI Physics</i> , 2015, 2, A27.	2.7	4
176	Congruency of tumour volume delineated by FET PET and MRSI. <i>EJNMMI Physics</i> , 2015, 2, A61.	2.7	3
177	Effects of dietary tryptophan and phenylalanine tyrosine depletion on phasic alertness in healthy adults - A pilot study. <i>Food and Nutrition Research</i> , 2015, 59, 26407.	2.6	12
178	Applications of PET imaging of neurological tumors with radiolabeled amino acids. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 59, 70-82.	0.7	21
179	Letter to the Editor: The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline [J Neurooncol 2014; 118:435-460]. <i>Journal of Neuro-Oncology</i> , 2014, 120, 665-666.	2.9	16
180	Reply: Discriminating Ability of <sup>18</sup> F-FET PET for Several Cerebral Neoplastic Lesions. <i>Journal of Nuclear Medicine</i> , 2014, 55, 176.2-176.	5.0	1

#	ARTICLE	IF	CITATIONS
181	NI-37 * INCREASED CEREBRAL AMINO ACID UPTAKE DURING AND AFTER EPILEPTIC DISORDERS MIMICS BRAIN TUMOR IN 18F-FET PET. <i>Neuro-Oncology</i> , 2014, 16, v146-v146.	1.2	2
182	Relationship of regional cerebral blood flow and kinetic behaviour of O-(2-18F-fluoroethyl)-L-tyrosine uptake in cerebral gliomas. <i>Nuclear Medicine Communications</i> , 2014, 35, 245-251.	1.1	18
183	NI-19 * THE USE OF DYNAMIC O-(2-[18F]fluoroethyl)-L-TYROSINE-PET IN THE CLINICAL EVALUATION OF BRAIN TUMORS IN CHILDREN AND ADOLESCENTS. <i>Neuro-Oncology</i> , 2014, 16, v142-v142.	1.2	1
184	<sup>68</sup> Ga-DOTATATE-positron emission tomography imaging in spinal meningioma. <i>Journal of Craniovertebral Junction and Spine</i> , 2014, 5, 44.	0.8	7
185	Dynamic analysis of MR-PET data on brain tumors. <i>EJNMMI Physics</i> , 2014, 1, A56.	2.7	1
186	Adapting MR-BrainPET scans for comparison with conventional PET: experiences with dynamic FET-PET in brain tumours. <i>EJNMMI Physics</i> , 2014, 1, A64.	2.7	0
187	Comparison of <sup>18</sup> F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 540-545.	5.0	115
188	Histogram analysis reveals a better delineation of tumor volume from background in 18F-FET PET compared to CBV maps in a hybrid PET-MR studie in gliomas. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2014, 734, 175-178.	1.6	2
189	Isomers of 4- <sup>18</sup> F-fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET. <i>Current Radiopharmaceuticals</i> , 2014, 7, 123-132.	0.8	13
190	Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 22-33.	6.4	158
191	Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas. <i>Nuclear Medicine and Biology</i> , 2013, 40, 795-800.	0.6	24
192	Advances in multimodal neuroimaging: Hybrid MR-PET and MR-PET-EEG at 3T and 9.4T. <i>Journal of Magnetic Resonance</i> , 2013, 229, 101-115.	2.1	67
193	Meningioangiomas in a patient with progressive focal neurological deficit-case report and review of literature. <i>British Journal of Neurosurgery</i> , 2013, 27, 253-255.	0.8	10
194	Advances in hybrid MR-PET at 3T and 9.4T in humans. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2013, 702, 16-21.	1.6	5
195	Detection of Remote Neuronal Reactions in the Thalamus and Hippocampus Induced by Rat Glioma Using the PET Tracer <i>Cis</i> -4-[ <sup>18</sup> F]Fluoro-D-Proline. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 724-731.	4.3	8
196	Diagnostic Performance of <sup>18</sup> F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 229-235.	5.0	167
197	Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington's disease. <i>Behavioural Brain Research</i> , 2013, 239, 15-26.	2.2	23
198	Sensitivity of intraoperative 5-aminolevulinic acid fluorescence compared with PET using O-(2-18F-fluoroethyl)-L-tyrosine to detect cerebral gliomas. <i>Neurological Research</i> , 2013, 35, 329-330.	1.3	0

#	ARTICLE	IF	CITATIONS
199	Clinical value of 2-deoxy-[18F]fluoro-d-glucose positron emission tomography in patients with cervical spondylotic myelopathy. <i>Neurosurgical Focus</i> , 2013, 35, E2.	2.3	10
200	Hypermetabolism in <sup>18</sup> F-FDG PET Predicts Favorable Outcome Following Decompressive Surgery in Patients with Degenerative Cervical Myelopathy. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1577-1583.	5.0	17
201	Replay: Being Sensitive: to Specify When Amino Acid Tracers Accumulate in a Brain Lesion. <i>Journal of Nuclear Medicine</i> , 2013, 54, 826.2-827.	5.0	0
202	5-Aminolevulinic Acid and 18F-FET-PET as Metabolic Imaging Tools for Surgery of a Recurrent Skull Base Meningioma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013, 74, 211-216.	0.8	29
203	Reply to "[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.. <i>Neuro-Oncology</i> , 2013, 15, 816-817.	1.2	13
204	The Use of <sup>18</sup> F-Fluoroethyl-L-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1217-1222.	5.0	47
205	Clinical value of O-(2-[18F]-fluoroethyl)-L-tyrosine positron emission tomography in patients with low-grade glioma. <i>Neurosurgical Focus</i> , 2013, 34, E3.	2.3	23
206	PET Imaging of Brain Tumors. <i>Medical Radiology</i> , 2013, , 121-134.	0.1	1
207	Role of <sup>18</sup> F-Fluoroethyl-L-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2046-2054.	5.0	108
208	Monitoring of Radiochemotherapy in Patients with Glioblastoma Using <sup>18</sup> F-Fluoroethyl-L-Tyrosine PET. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2046-2054.	1.4	19
209	Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2- <sup>18</sup> F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging. <i>Molecular Imaging</i> , 2013, 12, 7290.2013.00056.	1.4	38
210	Positron Emission Tomography in Diffuse Low-Grade Gliomas. , 2013, , 235-248.		0
211	Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2- <sup>18</sup> F-fluoroethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. <i>Molecular Imaging</i> , 2013, 12, 273-6.	1.4	18
212	Monitoring of radiochemotherapy in patients with glioblastoma using O-(2- <sup>18</sup> F-fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?. <i>Molecular Imaging</i> , 2013, 12, 388-95.	1.4	11
213	Assessment of Treatment Response in Patients with Glioblastoma Using <sup>18</sup> F-Fluoroethyl-L-Tyrosine PET in Comparison to MRI. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1048-1057.	5.0	184
214	Cost-Effectiveness Analysis of Amino Acid PET-Guided Surgery for Supratentorial High-Grade Gliomas. <i>Journal of Nuclear Medicine</i> , 2012, 53, 552-558.	5.0	32
215	Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide. <i>Journal of Clinical Oncology</i> , 2012, 30, e180-e183.	1.6	49
216	Discrepant MR and [ <sup>18</sup> F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure. <i>Case Reports in Oncology</i> , 2012, 5, 493-497.	0.7	13

#	ARTICLE	IF	CITATIONS
217	Positron Emission Tomography Imaging of Meningioma in Clinical Practice. <i>Neurosurgery</i> , 2012, 70, 1033-1042.	1.1	35
218	Multimodal imaging utilising integrated MR-PET for human brain tumour assessment. <i>European Radiology</i> , 2012, 22, 2568-2580.	4.5	64
219	Role of $^{18}\text{F}$ -Fluoroethyl-L-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1367-1374.	5.0	171
220	Brain Tumors. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 356-370.	4.6	129
221	[ $^{18}\text{F}$ ]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1077-1080.	0.6	11
222	Molecular Imaging of Brain Tumors. <i>Neuroinformatics</i> , 2012, , 345-357.	0.3	2
223	Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 334-339.	2.0	108
224	Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1089-1096.	6.4	47
225	Brain Tumors: Diagnostic Impact of PET Using Radiolabelled Amino Acids. , 2011, , 117-126.		0
226	Finding the anaplastic focus in diffuse gliomas: The value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 541-547.	1.4	151
227	High resolution BrainPET combined with simultaneous MRI. <i>Nuklearmedizin - Nuclear Medicine</i> , 2011, 50, 74-82.	0.7	138
228	Comparison of $^{18}\text{F}$ -FET PET and 5-ALA fluorescence in cerebral gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 731-741.	6.4	140
229	Prognostic Value of Early [ $^{18}\text{F}$ ]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 176-184.	0.8	132
230	Assessment of PET Tracer Uptake in Hormone-Independent and Hormone-Dependent Xenograft Prostate Cancer Mouse Models. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1654-1663.	5.0	39
231	Prognostic Value of $^{18}\text{F}$ -FDG PET in Monosegmental Stenosis and Myelopathy of the Cervical Spinal Cord. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1385-1391.	5.0	25
232	Clinical Evaluation of Primary Brain Tumor: O-(2-[ $^{18}\text{F}$ ]Fluorethyl)-L-Tyrosine Positron Emission Tomography. , 2011, , 179-188.		0
233	MR-PET opens new horizons in neuroimaging. <i>Future Neurology</i> , 2010, 5, 807-815.	0.5	9
234	Regional impairment of $^{18}\text{F}$ -FDG uptake in the cervical spinal cord in patients with monosegmental chronic cervical myelopathy. <i>European Radiology</i> , 2010, 20, 2925-2932.	4.5	18

#	ARTICLE	IF	CITATIONS
235	Comparison of $^{18}\text{F}$ -Fluoroethyl-L-Tyrosine and $^3\text{H}$ -Methionine Uptake in Cerebral Hematomas. <i>Journal of Nuclear Medicine</i> , 2010, 51, 790-797.	5.0	33
236	Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison. <i>Radiation Oncology</i> , 2009, 4, 57.	2.7	59
237	Comparison of $^{18}\text{F}$ -FET and $^{18}\text{F}$ -FDG PET in brain tumors. <i>Nuclear Medicine and Biology</i> , 2009, 36, 779-787.	0.6	177
238	Cerebral kinetics of the dopamine D2 receptor ligand $^{123}\text{I}$ IBZM in mice. <i>Nuclear Medicine and Biology</i> , 2008, 35, 467-473.	0.6	10
239	Comparison of intravenous and intraperitoneal $^{123}\text{I}$ IBZM injection for dopamine D2 receptor imaging in mice. <i>Nuclear Medicine and Biology</i> , 2008, 35, 543-548.	0.6	10
240	cis-4- $^{18}\text{F}$ -Fluoro-L-proline fails to detect peripheral tumors in humans. <i>Nuclear Medicine and Biology</i> , 2008, 35, 895-900.	0.6	7
241	Correlative Imaging of Hypoxia and Angiogenesis in Oncology. <i>Journal of Nuclear Medicine</i> , 2008, 49, 515-516.	5.0	10
242	Prognostic Value of $^{18}\text{F}$ -Fluoroethyl-L-Tyrosine PET and MRI in Small Nonspecific Incidental Brain Lesions. <i>Journal of Nuclear Medicine</i> , 2008, 49, 730-737.	5.0	77
243	Comparison of $^{99\text{m}}\text{Tc}$ - and $^{18}\text{F}$ -Ubiquitin Autoradiography to Anti- <i>Staphylococcus aureus</i> Immunofluorescence in Rat Muscle Abscesses. <i>Journal of Nuclear Medicine</i> , 2008, 49, 995-999.	5.0	16
244	Diagnostics of Cerebral Gliomas With Radiolabeled Amino Acids. <i>Deutsches Arzteblatt International</i> , 2008, 105, 55-61.	0.9	22
245	Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4- $^{18}\text{F}$ -Fluoro-D-Proline. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1482-1491.	5.0	19
246	Prognostic Value of O-(2- $^{18}\text{F}$ -Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2007, 48, 519-527.	5.0	171
247	Differential Uptake of O-(2- $^{18}\text{F}$ -Fluoroethyl)-L-Tyrosine, L- $^3\text{H}$ -Methionine, and $^3\text{H}$ -Deoxyglucose in Brain Abscesses. <i>Journal of Nuclear Medicine</i> , 2007, 48, 2056-2062.	5.0	86
248	O-(2- $^{18}\text{F}$ -fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. <i>Nuclear Medicine and Biology</i> , 2006, 33, 287-294.	0.6	317
249	Differential uptake of $^{18}\text{F}$ FET and $^3\text{H}$ -methionine in focal cortical ischemia. <i>Nuclear Medicine and Biology</i> , 2006, 33, 1029-1035.	0.6	55
250	$^{18}\text{F}$ -FET PET compared with $^{18}\text{F}$ -FDG PET and CT in patients with head and neck cancer. <i>Journal of Nuclear Medicine</i> , 2006, 47, 256-61.	5.0	67
251	$^{18}\text{F}$ -FET PET differentiation of ring-enhancing brain lesions. <i>Journal of Nuclear Medicine</i> , 2006, 47, 776-82.	5.0	91
252	Preferred Stereoselective Transport of the D-isomer of cis-4- $^{18}\text{F}$ -fluoro-proline at the Blood-Brain Barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 607-616.	4.3	36

#	ARTICLE	IF	CITATIONS
253	O-(2-[18F]fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 422-429.	6.4	187
254	Evaluation of new 18F-labeled amino acids for brain PET. <i>Anatomy and Embryology</i> , 2005, 210, 455-461.	1.5	7
255	Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. <i>Journal of Neurosurgery</i> , 2005, 102, 318-327.	1.6	170
256	O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. <i>Brain</i> , 2005, 128, 678-687.	7.6	537
257	Fluorine-18 <sup>18</sup> F-labeled fluorodeoxyglucose <sup>18</sup> F positron emission tomography studies of acute brainstem Lyme neuroborreliosis. <i>Journal of Neurosurgery</i> , 2005, 102, 927-929.	1.6	10
258	Preferred stereoselective brain uptake of d-serine <sup>18</sup> F a modulator of glutamatergic neurotransmission. <i>Nuclear Medicine and Biology</i> , 2005, 32, 793-797.	0.6	44
259	PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results. <i>Journal of Nuclear Medicine</i> , 2005, 46, 411-6.	5.0	75
260	Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas?. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 758-764.	3.4	69
261	Imaging of gliomas with Cis-4-[18F]fluoro-L-proline. <i>Nuclear Medicine and Biology</i> , 2004, 31, 67-75.	0.6	17
262	Molecular transport mechanisms of radiolabeled amino acids for PET and SPECT. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1435-6.	5.0	25
263	Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 519-524.	6.4	97
264	Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. <i>Nuclear Medicine and Biology</i> , 2003, 30, 501-508.	0.6	139
265	Tumor-free survival of 7 years after gene therapy for recurrent glioblastoma. <i>Neurology</i> , 2003, 61, 270-271.	1.1	5
266	Amino Acid Transport Studies in Brain Tumors. , 2003, , 477-485.		3
267	Transport of cis- and trans-4-[18F]fluoro-L-proline in F98 glioma cells. <i>Nuclear Medicine and Biology</i> , 2002, 29, 685-692.	0.6	25
268	3-[123I]iodo- $\beta$ -methyl-L-tyrosine: uptake mechanisms and clinical applications. <i>Nuclear Medicine and Biology</i> , 2002, 29, 625-631.	0.6	69
269	Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 231-236.	6.4	35
270	Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas. <i>Child's Nervous System</i> , 2002, 18, 445-449.	1.1	61



#	ARTICLE	IF	CITATIONS
271	3-[123I]iodo- $\beta$ -methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 855-861.	2.1	33
272	3-[123I]iodo- $\beta$ -methyl-L-tyrosine transport and 4F2 antigen expression in human glioma cells. <i>Nuclear Medicine and Biology</i> , 2001, 28, 5-11.	0.6	12
273	Whole-body kinetics and dosimetry of cis-4-[18F]fluoro-L-proline. <i>Nuclear Medicine and Biology</i> , 2001, 28, 287-292.	0.6	18
274	Performance measurement of a new high-resolution detector system for I-131 thyroid studies. <i>IEEE Transactions on Nuclear Science</i> , 2001, 48, 625-627.	2.0	3
275	Development of a high resolution, 2D detector system for iodine-131-scintigraphy. <i>IEEE Transactions on Nuclear Science</i> , 2000, 47, 1085-1087.	2.0	6
276	Recent Advances of PET in the Diagnosis of Brain Tumors. , 1999, 33, 9-22.		15
277	Iodine-123 $\beta$ -methyl tyrosine single-photon emission tomography of cerebral gliomas: standardised evaluation of tumour uptake and extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 150-156.	6.4	15
278	Effect of glycaemic control on myocardial sympathetic innervation assessed by [ 123 I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. <i>Diabetologia</i> , 1998, 41, 443-451.	6.3	65
279	Evaluation of QT Interval Length, QT Dispersion and Myocardial m-iodobenzylguanidine Uptake in Insulin-Dependent Diabetic Patients with and Without Autonomic Neuropathy. <i>Clinical Science</i> , 1997, 93, 325-333.	4.3	39
280	Whole-body kinetics and dosimetry of 3-[123I]iodo- $\beta$ -methyltyrosine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1162-1166.	2.1	22
281	Whole-body kinetics and dosimetry of 3-[ 123 I]iodo- $\beta$ -methyltyrosine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1162-1166.	6.4	1
282	Effect of partial volume correction on muscarinic cholinergic receptor imaging with single-photon emission tomography in patients with temporal lobe epilepsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1156-1161.	6.4	0
283	SPECT versus PET. , 1995, , 237-247.		0
284	Cerebral Glucose Metabolism in Type 1 Diabetic Patients. <i>Diabetic Medicine</i> , 1994, 11, 205-209.	2.3	23
285	The influence of image resolution on the positron emission tomographic measurement of caudate glucose consumption. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1993, 20, 753-8.	2.1	1
286	Posthypoxic amnesia: regional cerebral glucose consumption measured by positron emission tomography. <i>Journal of the Neurological Sciences</i> , 1993, 118, 10-16.	0.6	30
287	On the influence of spatial resolution and of the size and form of regions of interest on the measurement of regional cerebral metabolic rates by positron emission tomography. , 1992, 37, 53-66.		9
288	Regional Cerebral Glucose Consumption Measured by Positron Emission Tomography in Patients with Unilateral Thalamic Infarction. <i>Cerebrovascular Diseases</i> , 1991, 1, 327-336.	1.7	19

#	ARTICLE	IF	CITATIONS
289	Changed Pattern of Regional Glucose Metabolism during Yoga Meditative Relaxation. <i>Neuropsychobiology</i> , 1990, 23, 182-187.	1.9	123
290	Quantification of the whole-body distribution of PET radiopharmaceuticals, applied to 3-N-([18F]fluoroethyl)piperone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1990, 16, 77-83.	2.1	16
291	Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography. <i>Journal of Neurology</i> , 1990, 237, 80-84.	3.6	36
292	CORTICAL AND SUBCORTICAL GLUCOSE CONSUMPTION MEASURED BY PET IN PATIENTS WITH HUNTINGTON'S DISEASE. <i>Brain</i> , 1990, 113, 1405-1423.	7.6	268
293	Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease. <i>Psychiatry Research</i> , 1989, 29, 361-362.	3.3	31
294	Investigations of brain tumours with 99Tcm-HMPAO SPECT. <i>Nuclear Medicine Communications</i> , 1989, 10, 325-334.	1.1	17
295	Blood brain barrier blocks transport of carboxyl-11C-nicotinic acid into human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1988, 14, 53-4.	2.1	3
296	Tomographic Studies of rCBF with [99mTc]-HM-PAO SPECT in Patients with Brain Tumors: Comparison with C15O2 Continuous Inhalation Technique and PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1988, 8, S90-S94.	4.3	29
297	Tomographic studies of rCBF with 99mTc-HM-PAO SPECT in comparison with PET in patients with primary brain tumors. <i>Neurosurgical Review</i> , 1987, 10, 23-24.	2.4	8
298	Performance measurement of a new high resolution detector system for I-131 thyroid studies. , 0, , .		0
299	Creating consistent 3D multi-modality data sets from autoradiographic and histological images of the rat brain. , 0, , .		3
300	PET Imaging in Glioblastoma: Use in Clinical Practice. , 0, , 155-174.		15
301	Surgery of Motor Eloquent Glioblastoma Guided by TMS-Informed Tractography: Driving Resection Completeness Towards Prolonged Survival. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
302	Repeated amino acid PET imaging for longitudinal monitoring of brain tumors. <i>Clinical and Translational Imaging</i> , 0, , .	2.1	1